Yu J, Ouyang W, Huang Z, Chen G, Zhou Y, Mao Y L, Zhang J H, Xie C H
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):336-339. doi: 10.3760/cma.j.cn112152-20190626-00397.
To investigate the outcomes of limited stage small cell lung cancer (L-SCLC) undergoing surgical therapy and to explore the value of adjuvant therapy for those patients. A retrospective analysis was initialed for the L-SCLC patients who underwent the surgical treatment in the Zhongnan Hospital of Wuhan University from January 2012 to December 2018. The median disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method. Cox regression was used to explore the prognostic factors. A total of 44 patients were included in our study. The median DFS was 25 months, 1- and 2-year DFS rate were 70.2% and 51.9%, respectively. The median OS was 41 months, 1- and 2- year OS rate were 88.4% and 69.9%, respectively. Multivariate analysis showed male (=6.56, =0.03), T3-4 (=6.23, =0.01), pathological lymph node metastasis (=6.52, =0.03) and adjuvant radiotherapy (=0.13, =0.002) were associated with disease relapse significantly. Moreover, pathological lymph node metastasis (=3.62, =0.01) coupled with sufficient adjuvant chemotherapy (≥4 cycles) (=0.12, =0.01) were independent prognostic factors of OS. Surgical therapy may be an alternative primary treatment for L-SCLC. Additional adjuvant radiotherapy can reduce the risk of recurrence. Giving sufficient course of adjuvant chemotherapy can improve OS.
探讨局限期小细胞肺癌（L-SCLC）手术治疗的疗效，并探索辅助治疗对这些患者的价值。对2012年1月至2018年12月在武汉大学中南医院接受手术治疗的L-SCLC患者进行回顾性分析。采用Kaplan-Meier法计算中位无病生存期（DFS）和总生存期（OS）。使用Cox回归分析探索预后因素。本研究共纳入44例患者。中位DFS为25个月，1年和2年DFS率分别为70.2%和51.9%。中位OS为41个月，1年和2年OS率分别为88.4%和69.9%。多因素分析显示，男性（=6.56，=0.03）、T3-4（=6.23，=0.01）、病理淋巴结转移（=6.52，=0.03）和辅助放疗（=0.13，=0.002）与疾病复发显著相关。此外，病理淋巴结转移（=3.62，=0.01）联合充分的辅助化疗（≥4周期）（=0.12，=0.01）是OS的独立预后因素。手术治疗可能是L-SCLC的一种替代主要治疗方法。额外的辅助放疗可降低复发风险。给予充分疗程的辅助化疗可改善OS。
